


# THE PRO CHOICE IN ARTHRITIS



It is commonly agreed that prostaglandins confer upon the gastric mucosa a resistance to erosion and damage.<sup>1</sup> This so called mucoprotection is compromised by the use of antiarthritic drugs which are prostaglandin synthetase inhibitors. It has been suggested that this is of great relevance to the observed level of gastric side-effects observed with this class of drug.

Lederfen in the stomach has little or no effect on the mucoprotection conferred by the endogenous prostaglandins.<sup>2</sup> Simply, unmetabolised Lederfen is not a prostaglandin synthetase inhibitor.

The major metabolites of Lederfen are however most potent PSIs, shown by in vitro studies to be twice as potent as indomethacin.<sup>2</sup> Thus, once Lederfen



has been absorbed – avoiding prostaglandin-associated gastric compromise – a powerful antiarthritic effect is observed. Lederfen has been found to be at least equal in clinical effectiveness to reference standards including naproxen,<sup>3</sup> indomethacin,<sup>4</sup> and aspirin.<sup>5</sup> But with significantly fewer side-effects.

Power without doubt. The pro-choice in arthritis.

## Lederfen

fenbufen TABLETS

the pro-drug way to  
control pain, stiffness  
and side-effects

**Indications:** Rheumatoid arthritis, osteoarthritis, ankylosing spondylitis. **Dosage: Adults:** One tablet in the morning and two at night. LEDERFEN is not a gastric irritant and is converted, following absorption into long-acting active metabolites. Consequently LEDERFEN is extremely unlikely to cause gastro-intestinal bleeding or ulceration. Furthermore, LEDERFEN may be used without dosage modification in elderly patients in whom mild to moderate renal impairment commonly occurs. **Contra-indications:** Hypersensitivity to propionic acid anti-inflammatory drugs or aspirin. **Precautions:** In patients with a history or evidence of active peptic or intestinal ulceration, and only when considered essential in pregnant and nursing women. **Side-effects:** LEDERFEN is well tolerated by most patients. Gastro-intestinal symptoms, and occasionally skin rash are the most commonly reported. **Legal Category:** POM. **Presentation:** Light blue, film coated, capsule shaped 300 mg tablets engraved "LL300," or capsules printed "Lederle 300 mg," in bottles of 100. **Basic NHS Cost:** £16.24 per 100 tablets or capsules. PL/0095/0081. Further information is available on request to the company. **Lederle Laboratories, a division of Cyanamid of Great Britain Limited, Fareham Road, Gosport, Hants PO13 0AS. Tel: (0329) 236131.** **References:** 1. Guth P.H. Ann Rev Med; 33: 183-196 (1982) 2. Birnbaum J. et al. Pharmacology; 25 (Suppl. 1): 27-38 (1982) 3. Khan F.M. to be published 4. Salzman R.T. Reid R.T. Eur J Rheum and Inflamm; 5 (3) 318-325 (1982) 5. Roden D.F. J Irish Med Assoc; 72 (No. 6.) 250-256 (1979).



Lederfen is a trademark.

# A RADICALLY NEW WAY TO DELIVER RELIEF FROM ARTHRITIS

unique pH-sensitive

ONCE-DAILY  
2 CAPSULES o.d.  
**Oruvail**

ketoprofen

Programmed to control your patients'  
symptoms 24 hours-a-day



dialysing membrane

ketoprofen

## IN THE STOMACH

the acid environment prevents  
release of active drug –  
minimising local gastric irritation.

## IN THE INTESTINE

the more alkaline environment  
initiates the gradual diffusion  
of ketoprofen from the tablets  
– minimising local irritation.

### Prescribing information

**Dosage:** Orally with food, 100-200mg once daily

**Contra-indications:** Recurring history of/ or peptic ulceration, chronic dyspepsia, use in children, in patients sensitive to aspirin or other non-steroidal anti-inflammatory drugs known to inhibit prostaglandin synthetase or with bronchial asthma or allergic disease

**Precautions:** Pregnancy, lactation. Dosage of concomitant protein binding drugs may need modification.

**Side-effects:** Occasional gastro-intestinal intolerance. Very rare gastro-intestinal haemorrhage/skin rashes.

**Presentation:** 100mg capsules PL 0012/0133

**Basic NHS Cost:** (Jul '82) 100 x 100mg capsules £18.38


Oruvail is a trade mark



**M&B May & Baker**

May & Baker Ltd, Dagenham, Essex RM10 7XS

MA 1413



# **'CORDEX'**

## **SELF-BINDING CASES**

*for easy and instant reference*

Made to hold one volume  
(6 issues) of your

### **ANNALS OF THE RHEUMATIC DISEASES**

Each case is handsomely  
bound with a colour to  
complement the journal.  
Spring nylon cords, to carry  
the journals, slide freely along  
the spine of the binder. The  
name of the journal is gold  
blocked on the spine. Date  
labels are also provided.

**Price:** Inland £4.00; Overseas US\$12.00  
including postage (air mail overseas) and packing


## **ORDER NOW**

*From:* The Subscription Manager,  
**ANNALS OF THE RHEUMATIC DISEASES**  
BMA House, Tavistock Square, London WC1H 9JR


# ABC OF OPHTHALMOLOGY

All the common problems are covered - visual defects, squints, glaucoma and cataracts - together with detailed instruction on examination, diagnosis and management.

**Order your copy now**  
**From: The Publisher,**  
**British Medical Journal,**  
**BMA House,**  
**Tavistock Square,**  
**London WC1H 9JR**  
*or any leading bookseller*



**This Publication  
is available in Microform.**



**University Microfilms International**

Please send additional information

for \_\_\_\_\_

Name \_\_\_\_\_ (name of publication)

Institution \_\_\_\_\_

Street \_\_\_\_\_

City \_\_\_\_\_

State \_\_\_\_\_ Zip \_\_\_\_\_

300 North Zeeb Road, Dept. P.R., Ann Arbor, Mi. 48106

**Carol-Nachman Award for  
Rheumatology—Wiesbaden**

This prize will be awarded annually for  
outstanding research-work in the field of  
rheumatology. It is worth

**DM 75,000**

Submission of work may be made up  
until 31st December each year.

*Further information is available from*  
The Chief Administrative Officer  
Prof. Dr. Med, K Miehlike  
Rheumaklinik 1, Langgasse 38  
D-6200 Wiesbaden  
Germany.

# HOW TO DO IT

Every doctor knows the sinking sensation induced by waiting one's turn for an examination viva and the social anxieties of changing jobs. The misery of first night nerves does not, however, disappear with time: each decade brings new challenges. On these occasions—chairing a committee, giving evidence in court, appearing on television—practical tips can be enormously helpful. The same is true of the many skills not taught in medical school—how to lecture, referee papers, edit, or use a library. All these and many more nuggets of down-to-earth advice have been collected from past issues of the *BMJ* to form a compendium for the novice—whatever his or her age or seniority.

**Price: Inland £4.00;  
Abroad US\$10.00 (including air mail postage)**

**Payment must be enclosed with order**

**Order your copy now from: The Publisher, British Medical Journal, BMA House,  
Tavistock Square, London WC1H 9JR or any leading bookseller**

Pregnant v. Use with

relevance of this is not yet clear.

prescribing information is available from Geigy.

## Night and day relief from arthritic pain

### Effective against morning stiffness<sup>2</sup>

# Long term activity in arthritis

**I**N the treatment of arthritis, relief of pain and inflammation is a major objective. The ultimate aim, however, is to restore mobility lost through painful, stiffened joints. This requires long-term, consistently effective control of pain and inflammation. Continuity of treatment is fundamental to the successful management of arthritis.

**P**RODUCT of Boots Research, Froben is designed for the long-term treatment of arthritis. Rapidly absorbed, it quickly reaches the affected joints bringing pain and inflammation firmly under control and maintaining that control over long periods of treatment. Drug accumulation does not occur and Froben is well tolerated by most patients. Froben is suitable for continuous treatment. Which is why it is effective.

**S**UITABLE for most arthritic patients, Froben is particularly valuable for those who need a high level of relief from pain and inflammation. Froben will provide that extra relief without the high incidence of side-effects often associated with the more potent of the anti-arthritic agents.



**F**ROBEN is an excellent anti-arthritic with which to start treatment. It is an excellent antiarthritic with which to continue treatment. With Froben, your arthritic patients will receive the full benefit of continuous, consistent long-term therapy.

**Froben**  
flurbiprofen

**Active in Arthritis**


**Prescribing Information:**

**Presentation:** Sugar-coated tablets, each containing either 50mg or 100mg of flurbiprofen. **Uses:** Froben is indicated in the treatment of rheumatoid disease, osteoarthritis and ankylosing spondylitis. **Dosage:** 150mg to 200mg daily in 3 or 4 divided doses. In patients with severe symptoms or disease of recent origin, or during acute exacerbations, the total daily dose may be increased to 300mg in divided doses. **Contra-indications, Warnings etc:** Froben should not be given to patients with peptic ulceration. Care should be taken when administering the drug to patients with asthma or who have experienced bronchospasm with other anti-inflammatory or analgesic agents. The safety of Froben during pregnancy or lactation has not been established. In animal experiments, no teratogenic effects were demonstrated but parturition was delayed and prolonged. **Side-effects:** dyspepsia, heartburn and headache are the commonest encountered. Occasional skin rashes have been reported. **Treatment of overdose:** gastric lavage and, if necessary, correction of serum electrolytes. There is no specific antidote. **Basic NHS Price:** 50mg tablets, 100 £8.24 100mg tablets, 100 £15.65. **Product Licence No:** 50mg tablets, PL0014/0167 100mg tablets, PL0014/0168. Further information is available on request.

If you have not yet used Froben, naturally you will wish to know more about the product than we can convey in this advertisement. We will gladly send you the Froben Clinical & Technical Review upon your request.

Name .....

Address .....

 The Boots Company Ltd Nottingham England



# STATISTICS IN PRACTICE

No doctor can afford to ignore statistics: most modern medical research uses statistics. This important and authoritative book, which is a collection of articles that have appeared in the BMJ, provides clear information on designing studies, applying statistical techniques, and interpreting studies that use statistics. It can be easily understood by those with no statistical training and should be read by all those who want to keep abreast of new developments.

Price: Inland £7.00; Overseas US\$27.50\*

\*including air mail postage overseas

## Order your copy now


From: The Publisher, British Medical Journal,  
BMA House, Tavistock Square,  
London WC1H 9JR  
or any leading bookseller

# STATISTICS IN PRACTICE

STATISTICS IN QUESTION  
Sheila M Gore

STATISTICS AND ETHICS IN MEDICAL RESEARCH  
Douglas G Altman

ARTICLES FROM THE BRITISH MEDICAL JOURNAL




# Stands out

## References:

1. McGill, P. E., *et al.* (1979) *IXth Congress of Rheumatology*, Wiesbaden. RSM: London, ICSS No. 28, 109
2. Bachmann, F., *ibid.* p.31
3. Bedi, S.S., Eberl, R., Million, R., Silas, A. M., (1983) data on file, Reckitt & Colman Pharmaceutical Division
4. Lipani, J. A., *ibid.* p.67
5. Uthgenant, H. & Letzel, H., (1981) *British Journal of Clinical Practice*, **35**, 229
6. Berry, H., *et al.* (1980) *Annals of the Rheumatic Diseases*, **39**, 473
7. Bach-Andersen, R., *et al.* (1982) *Scandinavian Journal of Rheumatology*, Supplement 45, 43
8. Cox, N. L. & Goodall, W., (1981) *XVIIth Int. Congr. Rheumatol.*, Paris, June 1981, published by the Medicine Publishing Foundation, Nov. 81, p.7
9. Ruotsi, A., Kajander, A. & Nuotio, P., (1983) Paper presented at Xth European Congress of Rheumatology, Moscow

**Presentation** Tablets of 300mg fenclufenac. **Indications** Chronic and sub-acute rheumatological conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis. **Dosage and Administration** Adults 600-1200mg (2-4 tablets) daily in divided doses (morning and night) with or after food. Fenac is not recommended for children. **Contra-indications** Active peptic ulceration or gastric bleeding. **Warnings** Fenac should

# among NSAIDs in early RA



Symptomatic  
relief

plus reduction of  
raised ESR and CRP

## FLENAC

fenclofenac



## a logical choice in early RA

Symptomatic relief comparable with other NSAIDs<sup>1,2,3</sup>

Good gastric tolerability<sup>4,5</sup>

Consistently shown to reduce raised ESR and CRP levels, and  
beneficially affect other laboratory values in RA—in  
comparisons with d-penicillamine,<sup>6</sup> gold,<sup>7,8</sup> oxychloroquine,<sup>9</sup>  
naproxen,<sup>1</sup> diclofenac<sup>3</sup>

not at present be prescribed for children or pregnant or lactating women. Flenac may potentiate the action of drugs which are highly protein bound such as anticoagulants and oral hypoglycaemics. Care should be taken when treating patients with known renal or hepatic dysfunction, eczema, asthma or sensitivity to other non-steroidal anti-inflammatory drugs. **Note** Flenac interferes with thyroid function tests. **Side-Effects**

Gastro-intestinal symptoms sufficient to require discontinuing treatment are rare. Rashes have occurred, generally these are mild and resolve shortly after withdrawal of the drug, although occasionally more severe reactions have occurred. **NHS Price** £12.88 pack of 100 (August 1983); P.L. 44 0060. Additional information is available from: Reckitt & Colman Pharmaceutical Division, Hull HU8 7DS. Tel. 0482 26151. Flenac is a registered trade mark.



# Osteoarthritis

## Flosint

indoprofen

### fast pain relief

*swift*

peak plasma  
levels achieved  
in less than two hours

*sure*

available in over  
25 countries - clinical  
use for up to six years

*simple*

**Rx**  400mg  200mg  
a.m. p.m.

# FLOSINT

INDOPROFEN

## towards mobility without pain

#### Prescribing Information

**Presentation** White, uncoated, biconvex, scored tablets containing 200 mg indoprofen. **Uses** Flosint is an analgesic anti-inflammatory indicated for the treatment of the arthritides, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and others. Its analgesic activity may be utilised in a variety of disorders characterised by mild to moderate pain such as lower limb ischaemia, episiotomy and other surgical and dental procedures, and malignancy. **Dosage and Administration** Adults: The recommended initial dosage of indoprofen is 200 - 800 mg daily in two to three divided doses, in some severe conditions it can be advantageous to increase the daily dosage to 800 mg. Maintenance therapy can be accomplished by reducing the dosage to the level which gives satisfactory relief of symptoms for prolonged periods. The tablets should be taken with food to increase tolerability. Children: Paediatric usage has not been established. **Contra-Indications, Warnings, etc.** **Contra-Indications:** Indoprofen is a propionic acid derivative and a prostaglandin synthetase inhibitor. It should not be given to patients with known sensitivity to this class of compounds or to patients with active peptic ulceration. **Warnings:** Bronchospasm may be precipitated in patients suffering from or with a previous history of bronchial asthma or allergic disease. Indoprofen is extensively protein bound and may displace oral anti-coagulants, sulphonylureas, etc. from binding sites. Dosage alterations may be needed in patients requiring concomitant treatment with these agents. Dosage reduction may be required in renal or hepatic impairment. **Pregnancy** Animal experiments show no evidence of teratogenicity. However, this class of compounds has been shown to delay parturition in animals. The use of indoprofen during pregnancy should be avoided if possible. **Adverse Effects:** The most common adverse reactions caused by indoprofen are gastro-intestinal, including dyspepsia and nausea. Haemorrhage can occur rarely, as well as peptic ulceration. Other effects include mild central nervous system symptoms, such as dizziness and headache, and also skin rashes of various types. Decrease in platelet count has been observed rarely and blood dyscrasias may uncommonly occur. Limited data available suggests that abnormal liver function may be further impaired by treatment with indoprofen. **Overdosage:** Gastric lavage and general supportive treatment should be carried out. There is no specific antidote. **Legal Category** POM. **Package Quantities** Containers of 100 tablets. **Basic NHS Cost** £16.00 per 100 tablets. **Product Licence Number** 3453/0034 April 1983.

Further information is available from  
MONTEDISON GROUP  
 **FARMITALIA CARLO ERBA LTD.**  
KINGMAN ROAD, HITCHIN, Herts SG4 7ET, ENGLAND

© 1983 Montedison Group. All rights reserved.